Amgen (AMGN) recently received positive topline data from its Phase 3 OASIZ 301 trial for dazodalibep in Sjögren's disease, a development that has renewed investor attention on the company's autoimmune pipeline. This clinical success coincides with significant stock performance, including a 27.6% gain year-to-date and a 5-year total shareholder return of 131.0%, suggesting strong longer-term momentum despite recent price volatility.
Despite the positive catalysts, the article presents a conflicting valuation narrative where AMGN trades at $418.13, above the average analyst target but below intrinsic value estimates derived from discounted cash flow (DCF) models. While one analysis suggests the stock is 16% overvalued based on multiples, an alternative DCF framework indicates the shares trade roughly 38% below estimated future cash flow value of $673.80, highlighting a divergence in market assumptions regarding the company's earning power and legacy drug erosion.
The article outlines specific structural risks that could impact Amgen's growth trajectory, particularly concerning its position in the GLP-1 obesity market. Key concerns include a lack of domestic manufacturing infrastructure compared to competitors like Eli Lilly and Novo Nordisk, regulatory friction surrounding the CNPV pilot program, and the fact that Amgen is a late entrant in a crowded arena where incumbents already hold fast-track approvals. Additionally, the company faces significant headwinds from legacy high-margin drugs like Prolia and Enbrel, which are currently eroding at a rate of 30% or more year-over-year.
📈 Phase 3 OASIZ 301 data boosts autoimmune pipeline attention.
📊 Stock up 27.6% YTD with 131.0% five-year total return.
💰 Trades at $418.13, above analyst targets but below DCF value.
⚠️ Lacks domestic GLP-1 supply chain compared to Eli Lilly and Novo Nordisk.
📉 Legacy drugs Prolia and Enbrel eroding over 30% year-over-year.
📈 Amgen reported positive topline data from its Phase 3 OASIZ 301 trial for dazodalibep in Sjögren's disease, boosting attention on its autoimmune pipeline.
📊 The stock has climbed 27.6% year-to-date and achieved a 5-year total shareholder return of 131.0%, indicating strong longer-term momentum.
💰 AMGN currently trades at $418.13, which is above the average analyst target but below some intrinsic value estimates derived from DCF models.
⚠️ The company lacks massive domestic GLP-1 supply chain infrastructure compared to competitors like Eli Lilly and Novo Nordisk.
🏛️ The CNPV pilot program faces severe legal durability and structural transparency questions, creating regulatory friction for future growth.
🐢 Amgen is a latecomer in the obesity market where incumbents like Novo Nordisk already secured fast-track approvals via CNPV.
📉 Legacy high-margin drugs Prolia and Enbrel are eroding at a brutal negative 30% or more year-over-year clip.
🔍 A DCF model suggests AMGN trades about 37.9% below an estimated future cash flow value of $673.80, implying potential underestimation of earning power.
📉 Another valuation analysis concludes that AMGN is priced for flawless execution with zero margin of safety against structural vacuum.
🚀 If Amgen executes smoothly on dazodalibep and stabilizes legacy drug erosion, it could put pressure on the cautious market narrative.
Bullish Signals
Phase 3 OASIZ 301 trial data validated autoimmune pipeline potential.
Stock gained 27.6% YTD with 131.0% five-year TSR.
DCF model shows stock trades 37.9% below estimated value.
Risk Factors
CNPV pilot faces severe legal risks by mid-2026.
Obesity market crowded; Novo Nordisk holds fast-track tokens.
Amgen reported positive topline data from its Phase 3 OASIZ 301 trial of dazodalibep in Sjögren's disease, validating its autoimmune pipeline potential.
The stock has delivered a 27.6% gain year-to-date and a 5-year total shareholder return of 131.0%, reflecting strong longer-term momentum.
A DCF model estimates AMGN trades about 37.9% below an estimated future cash flow value of $673.80, suggesting the market may be underestimating its earning power.
Risk Factors
The CNPV pilot program faces severe legal durability and structural transparency questions in mid-2026, posing a high-risk gamble for a 2027 thesis.
Amgen is a latecomer in the obesity market where incumbents like Novo Nordisk already hold fast-track tokens, creating a crowded arena.
Legacy high-margin drugs Prolia and Enbrel are eroding at a brutal negative 30% or more year-over-year clip, pressuring top-line growth.
The stock trades above the average analyst target, with some narratives framing the recent autoimmune win as already fully priced in.
Amgen Inc. stock closed at USD 418.60 on September 28, 2026, representing a gain of 0.96% from the previous close of USD 414.61. The trading activity reflects ongoing investor interest in the biotechnology firm's pipeline developments and regulatory milestones.
Significant progress was made for Amgen's IMDELLTRA therapy following an FDA approval on September 14, 2026, which updated prescribing information to reduce recommended monitoring time from 22 to 24 hours to just 6 to 8 hours in a healthcare setting. This regulatory change streamlines administration protocols and could enhance the drug's operational efficiency.
Earlier in September, Amgen announced positive interim results for its Phase 3 DeLLphi-305 study involving IMDELLTRA combined with AstraZeneca's Imfinzi. The trial met its primary endpoint of statistically significant improvement in overall survival compared to Imfinzi alone, while also achieving secondary endpoints for progression-free survival and objective response rate across 563 randomized patients.
These developments highlight Amgen's strategic advancements in oncology treatments, potentially strengthening its market position by improving patient outcomes and reducing clinical monitoring burdens. The combination therapy results suggest a robust efficacy profile that could influence future prescribing patterns and competitive dynamics within the immunotherapy sector.
📈 AMGN stock rose 0.96% to USD 418.60 on September 28, 2026.
✅ FDA approved reduced monitoring for IMDELLTRA first two doses.
🔬 Phase 3 DeLLphi-305 study met primary survival endpoint with IMDELLTRA plus Imfinzi.
📊 Trial of 563 patients met secondary endpoints for progression-free survival and response rate.
💼 Combination therapy showed enhanced efficacy versus Imfinzi alone in pivotal study.
📈 Amgen stock traded at USD 418.60 on September 28, 2026, gaining 0.96% from the prior close of USD 414.61.
✅ The FDA approved an update to IMDELLTRA prescribing information on September 14, 2026, reducing monitoring requirements from 22-24 hours to 6-8 hours for the first two doses.
🔬 Amgen's Phase 3 DeLLphi-305 study met its primary endpoint at an interim analysis in early September 2026, showing statistically significant overall survival improvement with IMDELLTRA plus Imfinzi.
📊 The DeLLphi-305 trial randomized 563 patients and successfully met secondary endpoints for progression-free survival and objective response rate.
💼 Amgen's combination therapy of IMDELLTRA with AstraZeneca's Imfinzi demonstrated enhanced efficacy compared to Imfinzi alone in the pivotal study.
Bullish Signals
FDA approved IMDELLTRA to reduce monitoring time to 6-8 hours.
DeLLphi-305 met primary endpoint with Imfinzi for overall survival.
Trial achieved secondary endpoints in 563 patients validating efficacy.
Bullish Signals
Amgen received FDA approval on September 14, 2026, to reduce monitoring time for IMDELLTRA from 22-24 hours to 6-8 hours, streamlining clinical administration and potentially improving patient compliance.
The Phase 3 DeLLphi-305 study met its primary endpoint of statistically significant overall survival improvement when IMDELLTRA was combined with AstraZeneca's Imfinzi compared to Imfinzi alone.
Amgen successfully achieved secondary endpoints in the DeLLphi-305 trial, including progression-free survival and objective response rate, validating the combination therapy's efficacy across 563 randomized patients.
Amgen Inc. shares closed at USD 410.86 on September 25, 2026, representing a gain of 1.19 percent or USD 4.82 from the previous session's close of USD 406.04. The stock opened at USD 408.25 and traded within an intraday range of USD 6.81, reaching a high of USD 411.00 before settling slightly below that peak.
The performance of Amgen's stock outpaced the broader market indices during the session, rising significantly more than the S&P 500's 0.53 percent advance. At the time of the report at 1:17:34 p.m. ET, trading volume stood at 684,284 shares, with the share price remaining well below its 52-week high of USD 447.03.
Market conditions on September 25 were influenced by declining oil prices and elevated long-term yields, with the 10-year Treasury yield at 5.225 percent. While Amgen's gain was solid, it trailed healthcare peer Moderna, which rose 1.46 percent, as broader market uncertainty persisted regarding geopolitical risks and monetary policy.
Analyst consensus for Amgen remained a Hold recommendation with a target price of USD 389.22 according to data from September 25. The stock maintained a substantial buffer above its 52-week low of USD 269.77, indicating continued investor interest despite the gap below recent highs.
📈 AMGN stock closed up 1.19% at USD 410.86.
📊 Intraday high reached USD 411.00 with volume of 684,284 shares.
💰 Stock trades USD 36.17 below its 52-week high of USD 447.03.
📝 Analyst consensus is Hold with a price target of USD 389.22.
📈 Amgen stock closed at USD 410.86, up 1.19 percent or USD 4.82 from the prior session's close of USD 406.04.
📊 The share price opened at USD 408.25 and reached an intraday high of USD 411.00 before settling.
📉 Trading volume was recorded at 684,284 shares as of 1:17:34 p.m. ET on September 25, 2026.
🏆 Amgen's gain exceeded the S&P 500's 0.53 percent advance by 0.66 percentage points.
💰 The stock traded USD 36.17 below its 52-week high of USD 447.03 and USD 141.09 above its low.
🌍 Market gains were driven by declining oil prices, with the 10-year Treasury yield at 5.225 percent.
🔬 Amgen's performance trailed healthcare competitor Moderna, which rose 1.46 percent during the same session.
📝 Analyst consensus recommendation is Hold with a price target of USD 389.22 based on September 25 data.
Amgen's stock price increased by 4.34% on September 23, 2026, closing at $410.24 on the Nasdaq. This upward movement occurred despite a broader decline in the Nasdaq Composite, which fell 1.13% to close at 26,936.04 points.
The rally was primarily driven by positive late-stage clinical trial results for dazodalibep, an experimental treatment for Sjogren disease. The drug successfully met its primary endpoint in the trial, validating its efficacy and advancing its development profile toward potential regulatory approval.
📈 Amgen stock rose 4.34% to close at $410.24 on September 23, 2026.
🧬 Experimental drug dazodalibep met primary late-stage trial goal for Sjogren disease.
📈 Jefferies raised Amgen price target to $410.00 following positive trial data.
📈 Amgen stock rose 4.34% to close at $410.24 on September 23, 2026.
🧬 The experimental drug dazodalibep met its primary late-stage trial goal for Sjogren disease.
📈 Jefferies raised its price target for Amgen to $410.00 following the positive trial data.
Bullish Signals
Stock gained 4.34% after dazodalibep met Sjogren trial goal.
Jefferies raised price target to $410 on successful trial.
Bullish Signals
Amgen stock gained 4.34% on September 23, 2026, closing at $410.24 after dazodalibep met its primary late-stage trial goal for Sjogren disease.
Analyst firm Jefferies raised its price target to $410.00 following the successful trial results for the experimental treatment.
Amgen Inc. shares rose 4.34% to close at $410.24 on September 22, 2026, driven by positive Phase 3 trial data for its drug candidate dazodalibep in Sjogren's disease. The OASIZ 301 study met its primary endpoint in adults with moderate-to-severe Sjogren's disease, significantly strengthening the company's pipeline outlook and investor sentiment regarding future commercial potential.
Financially, Amgen reported robust quarterly performance for the period ended June 30, 2026, delivering $10.05 billion in revenue and $6.29 in earnings per share. The EPS of $6.29 notably exceeded the consensus estimate of $5.62 by $0.67, while revenue grew 9.5% compared to the same quarter last year, demonstrating solid operational execution.
Analyst reaction was positive, with Jefferies raising its price target for Amgen stock from $367 to $410 following the news, although maintaining a Hold rating. The firm also increased its peak sales estimate for dazodalibep to $4.5 billion from $1 billion, highlighting the material valuation impact of the successful trial results.
Looking ahead, the company maintained its fiscal year 2026 EPS guidance range of $22.30 to $23.50, which aligns closely with analyst consensus. The next critical milestone is the OASIZ-303 data expected in the fourth quarter of 2026, which must be reported before a regulatory filing can be submitted for dazodalibep.
📈 Amgen stock gained 4.34% to $410.24 on positive dazodalibep Phase 3 data.
💰 Quarterly revenue hit $10.05B and EPS reached $6.29, beating estimates by $0.67.
📊 Revenue grew 9.5% year-over-year, reinforcing financial stability for fiscal year 2026.
🚀 Jefferies raised price target to $410 and peak dazodalibep sales estimate to $4.5B.
⏳ OASIZ-303 study data expected in Q4 2026 before regulatory filing.
📈 Amgen stock closed at $410.24 on September 22, 2026, gaining 4.34% as positive Phase 3 data for dazodalibep in Sjogren's disease lifted pipeline hopes.
💰 The company reported quarterly revenue of $10.05 billion and EPS of $6.29 for the quarter ended June 30, 2026, beating the consensus estimate by $0.67.
📊 Revenue grew 9.5% year-over-year, exceeding market expectations and reinforcing Amgen's financial stability during the fiscal year 2026.
🚀 Jefferies raised its price target for AMGN from $367 to $410 and increased peak sales estimates for dazodalibep to $4.5 billion following the trial success.
🔬 The OASIZ 301 Phase 3 study met its primary endpoint in adults with moderate-to-severe Sjogren's disease, validating the drug candidate's efficacy.
⏳ Another study (OASIZ-303) must report before regulatory filing, with data expected in the fourth quarter of 2026.
🎯 Amgen maintained fiscal year 2026 EPS guidance of $22.30 to $23.50, showing confidence in its near-term earnings delivery despite narrow consensus alignment.
📉 The stock trades at a P/E ratio of 25.50 with a market capitalization of $221.79 billion as of September 22, 2026.
Bullish Signals
Stock rose 4.34% to $410.24 on positive dazodalibep trial data.
Revenue hit $10.05B and EPS of $6.29, beating estimates by $0.67.
Jefferies raised price target to $410 and peak dazodalibep sales to $4.5B.
OASIZ 301 Phase 3 met primary endpoint boosting pipeline outlook.
Risk Factors
Dazodalibep regulatory filing depends on pending OASIZ-303 study results.
OASIZ-303 data not expected until Q4 2026, delaying commercial validation.
Bullish Signals
Amgen stock rose 4.34% to close at $410.24 on September 22, 2026, directly driven by positive Phase 3 trial data for dazodalibep in Sjogren's disease.
The company reported quarterly revenue of $10.05 billion and EPS of $6.29, with EPS beating the consensus estimate by $0.67.
Revenue grew 9.5% year-over-year compared to the comparable quarter ended June 30, 2026, demonstrating strong top-line performance.
Jefferies raised its price target for AMGN from $367 to $410 and increased peak sales estimates for dazodalibep to $4.5 billion following the successful trial.
The OASIZ 301 Phase 3 study met its primary endpoint in adults with moderate-to-severe Sjogren's disease, significantly strengthening the pipeline outlook.
Risk Factors
Another study (OASIZ-303) must report before regulatory filing can be submitted for dazodalibep, creating a dependency on future clinical milestones.
The OASIZ-303 data is not expected until the fourth quarter of 2026, leaving a gap before the commercial case for dazodalibep can be fully tested.
Amgen (AMGN) shares surged approximately 4% in premarket trading to reach $406.02 following the announcement of positive topline results from its Phase 3 clinical trial, OASIZ 301, for dazodalibep, an experimental treatment for Sjögren's disease. The study met its primary endpoint, demonstrating statistically meaningful improvements in systemic disease activity at Week 48 as measured by the ESSDAI index among 621 patients with moderate-to-severe conditions.
The trial data indicated that therapeutic benefits were observable as early as Week 4 and persisted through the full 48-week duration. Dazodalibep functions as a CD40L antagonist fusion protein designed to disrupt immune cell interactions driving the autoimmune disease. Notably, there are currently no FDA-approved medicines for Sjögren's, positioning dazodalibep as a potential first-in-class therapy if regulatory approval is granted.
Safety profiles observed in the trial were manageable, with common side effects including nasopharyngitis and hypertension occurring at mild to moderate levels. Discontinuation rates due to adverse events were low and comparable between treatment and placebo groups. Amgen plans to present full data at an upcoming medical conference, while a second Phase 3 study is expected to conclude in Q4 2026.
📈 AMGN stock rose ~4% premarket after positive Phase 3 dazodalibep results.
✅ OASIZ 301 met primary endpoint showing improvement at Week 48.
💊 Dazodalibep is a CD40L antagonist targeting immune cells for Sjögren's.
🛡️ Safety data showed low discontinuation rates with mild side effects.
🚀 Approval would make dazodalibep the first FDA treatment for Sjögren's.
📈 AMGN stock jumped roughly 4% in premarket trading to hit $406.02 after reporting positive Phase 3 trial results for its Sjögren's disease drug, dazodalibep.
✅ The OASIZ 301 study met its primary endpoint with patients showing statistically meaningful improvement in systemic disease activity at Week 48.
🔬 Dazodalibep demonstrated early efficacy improvements as soon as Week 4 that held through the end of the 48-week trial period.
💊 The drug is a CD40L antagonist fusion protein targeting T cells, B cells, and other immune cells to disrupt disease-driving interactions.
🛡️ Safety data showed low discontinuation rates due to side effects, which were mild to moderate and similar across treatment and placebo groups.
🚀 If approved, dazodalibep would be the first FDA-approved treatment for Sjögren's, a systemic autoimmune disease currently lacking approved medicines.
📅 Amgen plans to present full data from OASIZ 301 at an upcoming medical conference to provide further clarity on the drug's profile.
🔭 A second Phase 3 study, OASIZ 303, is underway and expected to wrap up in Q4 2026 for patients with moderate-to-severe symptomatic Sjögren's disease.
Bullish Signals
Stock jumped 4% to $406.02 on positive Phase 3 results.
OASIZ 301 trial met primary endpoint at Week 48.
Dazodalibep showed benefits by Week 4 through Week 48.
Drug is potential first-in-class therapy for Sjögren's.
Bullish Signals
Amgen stock jumped roughly 4% in premarket trading to hit $406.02 following positive topline results from the Phase 3 trial of its experimental Sjögren's disease drug, dazodalibep.
The OASIZ 301 trial met its primary endpoint with patients showing statistically meaningful improvement in systemic disease activity at Week 48.
Dazodalibep demonstrated therapeutic benefits as early as Week 4 that persisted through the full 48-week period of the study.
The drug represents a potential first-in-class therapy for Sjögren's, a condition currently lacking any FDA-approved medicines.
Amgen stock recently closed at USD 385.65 on the Nasdaq on September 18, 2026, positioning it just below the average analyst target price of approximately USD 387.69. The company has demonstrated strong earnings momentum in recent quarters, consistently beating market expectations and driving a positive market reaction that saw shares rise around 1.55% following the latest session.
Analyst consensus data compiled around mid-September 2026 indicates that while the current price leaves limited immediate upside from the average target, there remains significant potential for growth relative to the high analyst objective of USD 457.00. The stock has gained roughly 17.82% since the start of 2026, reflecting investor confidence in its earnings trajectory and solid fundamental performance within the large-cap healthcare sector.
Beyond earnings beats, Amgen benefits from a robust history of dividend growth, earning an A- grade for dividend growth alongside peers like AbbVie. This consistent payout track record makes the stock attractive to income-oriented investors, while the company maintains a substantial market capitalization of approximately USD 208.45 billion as of September 21, 2026.
📈 AMGN stock closed at $385.65 below analyst average target of $387.69.
Holds A- dividend grade with robust payout history.
Gained 17.82% since start of 2026.
Bullish Signals
Amgen stock recently closed at USD 385.65, trading just below the average analyst target of USD 387.69, signaling confidence from Wall Street analysts.
The company has reported strong earnings momentum in recent quarters with consistent beats versus market expectations, driving a positive 1.55% share price move.
Amgen holds an A- grade for dividend growth, demonstrating a robust history of increasing payouts that appeals to income-oriented investors.
The stock has gained approximately 17.82% since the start of 2026, indicating sustained investor confidence in its fundamental performance.
Amgen's stock price surged on September 18, 2026, closing at $385.65 on Nasdaq, representing a gain of 1.55% from the previous session. This positive market reaction was driven primarily by the company's updated financial outlook and its commitment to shareholder returns through a robust dividend program.
Management has officially raised its 2026 earnings per share guidance to a range of $22.30 to $23.50. This upward revision signals strong confidence within the biotech group that its core business operations are sufficient to cover and grow its dividend payments, moving away from reliance on financial engineering tactics.
Amgen maintains an attractive dividend profile for investors, paying a quarterly dividend of $2.52 per share. When annualized, this results in a total payout of $10.08 per share, implying a yield of approximately 2.6% at the current share price, which has attracted significant attention from income-focused investors.
📈 Amgen stock rose 1.55% to $385.65 on Sept 18, 2026.
🚀 Management raised 2026 EPS guidance to $22.30–$23.50 range.
💰 Company pays quarterly dividend of $2.52, annualizing to $10.08.
📊 Current price implies approximately 2.6% dividend yield for investors.
🛡️ Leadership confirms operating performance will cover and grow the dividend.
📈 Amgen stock closed at $385.65 on September 18, 2026, gaining 1.55% following positive news.
🚀 Management raised 2026 earnings per share guidance to a range of $22.30 to $23.50.
💰 The company pays a quarterly dividend of $2.52, annualizing to $10.08 per share.
📊 The current share price implies a dividend yield of approximately 2.6% for investors.
🛡️ Leadership signals confidence that operating performance will cover and grow the dividend.
Bullish Signals
Stock surged 1.55% to $385.65 on Sept 18, 2026.
Management raised 2026 EPS guidance to $22.30-$23.50.
Offers strong 2.6% dividend yield with $10.08 annual payout.
Bullish Signals
Amgen stock surged 1.55% to close at $385.65 on September 18, 2026, driven by rising earnings guidance.
Management raised 2026 EPS guidance to a range of $22.30 to $23.50, demonstrating confidence in business growth.
The company offers a strong dividend yield of approximately 2.6% with an annualized payout of $10.08 per share.
Amgen (AMGN) stock valuation has seen a modest lift as analyst models update fair value targets from US$371.93 to US$388.03, reflecting shifts in revenue growth assumptions from 2.93% to 3.50% and net profit margin expectations rising to 25.15%. This adjustment incorporates a slightly higher future P/E multiple of 25.1x and a discount rate increase to 7.96%, signaling evolving market pricing for the biopharmaceutical giant.
Market sentiment remains mixed among major financial institutions, with several firms including UBS, Argus, TD Cowen, Scotiabank, Oppenheimer, Barclays, Bernstein, Wells Fargo, and Piper Sandler raising price targets to a US$420-US$460 range. These bullish moves cite strong commercial execution, recent Q2 earnings beats, higher guidance, and robust long-term sales potential for key cholesterol and cardiovascular franchises like Repatha and Lipfendra.
Conversely, HSBC downgraded Amgen to Hold with a reduced target of US$425, while BMO Capital adopted a neutral Market Perform stance at US$450. These bearish adjustments highlight concerns over ongoing loss of exclusivity on existing products, competitive pressures from biosimilars, and the need for greater clarity on the sales trajectory of its pipeline candidate MariTide.
📈 Analysts raise Amgen fair value targets to US$388-US$460 citing earnings beats.
💊 Prescription data supports higher long-term sales for Repatha and Lipfendra.
⚠️ BMO warns of exclusivity losses and MariTide competitive uncertainty risks.
🧬 Late-stage pipeline in obesity and oncology could drive future high-margin launches.
📈 Amgen's updated analyst model raises fair value price target to US$388.03 from US$371.93, reflecting improved revenue growth assumptions and profit margin expectations.
🔍 Multiple analysts including UBS, Argus, TD Cowen, Scotiabank, and Oppenheimer raised targets to US$420-US$460 citing strong product portfolio performance and Q2 earnings beats.
💊 Wells Fargo and Piper Sandler increased targets to US$435 based on prescription data supporting higher long-term sales for Repatha and Lipfendra.
📉 HSBC downgraded Amgen to Hold and cut its target to US$425, noting that current stock price aligns closely with fair value with limited near-term upside.
⚠️ BMO Capital shifted to a neutral Market Perform rating at US$450 due to ongoing loss of exclusivity headwinds and uncertainty surrounding MariTide's competitive profile.
📊 Analyst models show revenue growth assumption shifting from 2.93% to 3.50% while net profit margin expectations rise from 24.84% to 25.15%.
🧬 Key investment themes include Amgen's late-stage pipeline in obesity, type 2 diabetes, cardiovascular disease, and oncology which could drive future high-margin launches.
🛡️ Strategic diversification efforts focus on biosimilars portfolio expansion, digital transformation initiatives, and reaching under-treated patient groups to stabilize revenue base.
⚖️ Primary risks identified include drug pricing pressure, biosimilar competition affecting products like Prolia, heavy R&D and manufacturing spend, and regulatory uncertainty.
Bullish Signals
Analysts raised price targets to US$420-US$460 citing strong execution and earnings beats.
Barclays and Bernstein highlighted product strength and higher guidance for confident forecasts.
Wells Fargo lifted target to US$435 based on Repatha and Lipfendra sales potential.
Fair value target increased from US$371.93 to US$388.03 with improved revenue growth assumptions.
Net profit margin assumptions adjusted upward from 24.84% to 25.15% for stronger profitability.
Risk Factors
HSBC downgraded to Hold with $425 price target.
BMO neutral at $450 citing exclusivity loss risks.
Risks include pricing pressure, biosimilars, and R&D spend.
Bullish Signals
Analysts including UBS, Argus, TD Cowen, Scotiabank, and Oppenheimer raised price targets to a US$420-US$460 range citing strong commercial execution and Q2 earnings beats.
Barclays and Bernstein highlighted broad product strength and higher guidance as support for confident forecasts of Amgen's execution across key franchises.
Wells Fargo and Piper Sandler lifted targets to US$435 based on external survey work and prescription data supporting higher long-term sales potential for Repatha and Lipfendra.
Updated analyst model increases fair value price target from US$371.93 to US$388.03, reflecting improved revenue growth assumptions shifting from 2.93% to 3.50%.
Net profit margin assumptions have been adjusted upward from 24.84% to 25.15%, indicating analysts expect stronger profitability in the coming periods.
Risk Factors
HSBC downgraded Amgen to Hold and cut its price target to US$425, stating that after strong execution the stock price more closely matches fair value with limited near-term upside.
BMO Capital shifted to a neutral Market Perform stance at US$450 citing ongoing loss of exclusivity headwinds and a need for more clarity on the competitive profile of MariTide.
Key risks include drug pricing pressure, biosimilar competition on products such as Prolia, heavy R&D and manufacturing spend, regulatory uncertainty, and demographic shifts.
Amgen (AMGN) shares dropped approximately 5% on September 16, 2026, closing lower on the Nasdaq amid a broader sector downturn. The decline was primarily driven by fresh clinical data in the cardiovascular space that negatively impacted investor sentiment across the biopharmaceutical industry.
The stock's performance suffered significantly from Novartis' recent failure in cardiovascular medicine trials, which created a ripple effect throughout the sector. As Amgen holds a substantial weighting in the Dow Jones Industrial Average, it was disproportionately affected by the index's 1.21% fall and the specific reassessment of cardiometabolic drug pipelines following these setbacks.
Broader macroeconomic pressures further exacerbated the sell-off, with risk-off sentiment intensifying after the Federal Reserve signaled an upcoming rate hike. Investors are now closely monitoring Amgen's pipeline developments and broader market dynamics as they navigate this volatile environment.
📉 Amgen stock fell 5% on Sept 16, 2026, closing lower on Nasdaq.
💊 Cardiovascular clinical data weighed heavily on Amgen's performance decline.
Amgen stock closed at $381.96 on September 14, 2026, rising 1.1 percent to outperform the broader market as the S&P 500 and Nasdaq Composite declined.
The positive price movement was driven by specific regulatory developments regarding the company's oncology portfolio rather than general sector trends or macroeconomic factors.
Key catalysts included FDA approval for Imdelltra, a bispecific T-cell engager therapy, which now features a reduced monitoring time requirement. This regulatory win simplifies the treatment protocol and is expected to positively influence adoption trends within the oncology market.
📈 Amgen shares rose 1.1% to $381.96 on Sept 14, 2026.
✅ FDA approved Imdelltra with reduced monitoring time requirements.
🔬 Regulatory milestone drives adoption for Amgen's oncology pipeline.
📈 Amgen shares gained 1.1 percent to close at $381.96 on September 14, 2026, defying a broader market decline where the S&P 500 fell 0.5 percent.
✅ The FDA granted approval for Imdelltra with a reduced monitoring time requirement, streamlining the administration protocol for this bispecific T-cell engager therapy.
🔬 This regulatory milestone is expected to drive adoption trends for Amgen's oncology pipeline by making the treatment more accessible and operationally efficient.
Bullish Signals
Stock rose 1.1% to $381.96, outperforming S&P 500 and Nasdaq.
FDA approval for Imdelltra simplifies protocol, accelerating oncology adoption.
Bullish Signals
Amgen stock rose 1.1 percent to $381.96, outperforming the S&P 500 and Nasdaq Composite during a broader market decline.
The FDA approval for Imdelltra with reduced monitoring time simplifies the treatment protocol, potentially accelerating adoption in the oncology sector.
Amgen (AMGN) shares have experienced a sharp five-day decline of approximately 15%, erasing roughly $36 billion from its market capitalization and leaving the stock trading at about $204 billion. This significant drop contrasts with broader market performance, as the S&P 500 declined by only 1.2% during the same period, placing Amgen among a select group of stocks facing substantial selling pressure.
The recent selloff is directly attributed to clinical trial fallout in the cardiovascular space, specifically following Novartis's failure to meet its primary endpoint for its pelacarsen study. This event cast doubt on the commercial viability of Amgen's competing Phase 3 candidate, olpasiran, triggering a direct spillover effect that drove down AMGN shares despite the company's otherwise sturdy underlying business metrics.
Despite the short-term price action, Amgen reports robust trailing fundamentals with revenue growth of 9.1% over the last twelve months and an operating margin of 30.0%, both exceeding S&P 500 medians. The stock currently trades at a price-to-earnings multiple of 23.3, which is below the sector median of 25.1, while maintaining a healthy free cash flow yield of 5.0%.
Longer-term performance remains positive with returns of +7.2% over three months and +39.2% over twelve months, suggesting the recent slide may represent a market reassessment rather than a fundamental deterioration. Analysts view such streaks as signals to re-evaluate investment theses against underlying business data rather than immediate instructions to alter positions.
📉 Stock fell 15% in five days, erasing $36B value due to Novartis trial impact.
📈 Revenue grew 9.1% YoY, outpacing S&P 500 median of 8.3%.
💰 Operating margins hit 30.0%, well above the 18.6% sector median.
📊 P/E multiple is 23.3, trading below the Health Care sector median of 25.1.
💵 Free cash flow yield stands at 5.0% with strong generation capabilities.
📉 Amgen stock has fallen 15% over five consecutive trading days, erasing approximately $36 billion in market value.
💊 The decline is linked to Novartis's failed Phase 3 trial for pelacarsen, which negatively impacted investor sentiment toward Amgen's competing olpasiran candidate.
📈 Revenue growth remains strong at 9.1% year-over-year, outpacing the S&P 500 median of 8.3% over the trailing twelve months.
💰 Operating margins stand at 30.0%, significantly higher than the 18.6% median for the broader index.
📊 The stock trades at a P/E multiple of 23.3, which is below the Health Care sector median of 25.1.
💵 Amgen maintains a free cash flow yield of 5.0%, indicating solid cash generation capabilities.
📅 Longer-term momentum persists with +7.2% returns over the trailing three months and +39.2% over twelve months.
Bullish Signals
Revenue grew 9.1%, exceeding S&P 500 median of 8.3%.
Operating margin stands at 30.0%, well above index median.
Free cash flow yield is 5.0%, showing strong generation.
Stock returned +7.2% in three months and +39.2% yearly.
Risk Factors
Shares dropped 15% in 5 days, erasing $36B value.
Competitor trial failure casts doubt on olpasiran viability.
Joining 45 S&P 500 stocks with 5-day losing streak.
Bullish Signals
Revenue growth of 9.1% over the last twelve months exceeds the S&P 500 median of 8.3%, demonstrating resilient top-line performance.
The company maintains a robust operating margin of 30.0%, which is well above the index median of 18.6%.
Amgen generates a free cash flow yield of 5.0%, reflecting strong cash generation relative to its market capitalization.
Despite recent volatility, the stock has delivered +7.2% returns over the trailing three months and +39.2% over twelve months.
Risk Factors
Shares have dropped 15% over five consecutive days, erasing $36 billion in market value due to a sharp selloff.
The stock price fell following Novartis's failed Phase 3 trial for pelacarsen, casting doubt on the commercial viability of Amgen's competing olpasiran candidate.
The recent decline places AMGN among 45 other S&P 500 stocks on losing streaks of five days or more, indicating significant short-term momentum weakness.
Amgen stock fell approximately 1.34% to close at USD 377.35 on September 11, 2026, following a downgrade from Buy to Hold by HSBC. The bank cut its price target to USD 425 from USD 445, arguing that the stock has re-rated significantly after strong execution and now trades close to fair value. This sentiment is reinforced by a consensus analyst price target of roughly USD 381.68, which sits only about USD 4 above the current share price, signaling limited near-term upside.
Despite the negative analyst reaction, Amgen reported robust financial results for the second quarter of 2026. Revenue rose 9.5% year-over-year to reach USD 10.05 billion, surpassing consensus estimates of USD 9.43 billion. Diluted earnings per share also beat expectations, coming in at USD 6.29 compared to an analyst forecast of USD 5.62, representing a 4.5% increase from the prior-year quarter.
Key growth drivers include the cholesterol-lowering drug Repatha, which generated USD 953 million in revenue during the quarter, up 37% sequentially. Analysts are now focusing on upcoming pipeline readouts, particularly data from the MariTide obesity trial, as the next major catalyst for the company amidst intensifying competition in the therapeutic space.
The market capitalization of Amgen stood at USD 204.01 billion at the time of the close. While the stock remains well below its 52-week high of USD 447.03, it sits roughly USD 107 above its low. The prevailing analyst sentiment is balanced, with ratings split between Buy, Hold, and Sell categories, suggesting investors are weighing current earnings strength against future trial outcomes.
📉 HSBC downgraded AMGN to Hold with a USD 425 price target.
Amgen (AMGN) received a downgrade to Market Perform from Outperform at BMO Capital on Tuesday, September 8, 2026. The analyst firm adjusted its rating for the biotech giant while maintaining a price target of $450 per share.
This negative analyst action occurred amidst a broader market environment where Wall Street returned from summer vacation to brace for potential Federal Reserve rate hikes following strong August payrolls data that crushed expectations.
The downgrade represents a shift in sentiment regarding the company's outlook, contrasting with other recent analyst moves in the sector such as upgrades for Intel and Lockheed Martin, though specific fundamental drivers for Amgen's downgrading were not detailed in this report.
📉 BMO downgraded AMGN to Market Perform from Outperform.
💰 BMO maintains $450 price target for AMGN shares.
📅 Analyst action occurred on Tuesday, September 8, 2026.
📉 Amgen was downgraded to Market Perform from Outperform by BMO Capital.
💰 BMO Capital maintains a $450 price target for Amgen shares following the rating change.
📅 The analyst action took place on Tuesday, September 8, 2026, as part of a daily roundup of Wall Street research calls.
Risk Factors
Downgraded to Market Perform by BMO Capital.
Reduced confidence in near-term prospects due to Fed rate hike fears.
Risk Factors
Amgen was downgraded to Market Perform from Outperform by BMO Capital, signaling reduced analyst confidence in the company's near-term prospects.
The downgrade occurred while the broader market faced pressure from strong employment data that increased the likelihood of a Federal Reserve rate hike.
Amgen Inc. (NASDAQ: AMGN) reported solid Q2 2026 financial results with revenue reaching $10.1 billion, representing a 10% year-over-year increase. Non-GAAP EPS rose 4% to $6.29, driven by robust growth in key products which increased 26%. The company generated $3.5 billion in free cash flow during the quarter, providing substantial capital flexibility for future investments and shareholder returns.
Despite positive momentum in its core portfolio, Amgen faces significant headwinds from biosimilar competition affecting its mature franchises. Revenue from Prolia declined 32% while XGEVA revenue fell 34%. To counter these challenges, management raised its full-year 2026 revenue guidance midpoint to $39.4 billion, signaling confidence in offsetting erosion with new product launches and pipeline assets like olpasiran.
Analyst sentiment remains positive, with Wells Fargo raising its price target to $435 from $400 on September 4. The firm cited potential upside from the cardiovascular drug HORIZON and the expanded mortality benefits of Repatha, which recently showed a 20% reduction in death risk for high-risk adults. Hedge fund positioning also shows support, with major investors like D.E. Shaw increasing their stakes significantly.
The article concludes that while Amgen presents a viable investment case supported by strong cash flow and pipeline potential, investors must monitor the effectiveness of new launches against biosimilar erosion. The company's ability to maintain margin expansion will depend on successfully navigating competitive pressures in legacy segments while capitalizing on growth opportunities in oncology and cardiovascular therapies.
📈 Amgen Q2 revenue rose 10% to $10.1B with EPS up 4%.
Amgen reported Q2 2026 revenue of $10.1 billion, a 10% year-over-year increase driven by robust growth in key products which advanced 26%.
The company generated $3.5 billion in free cash flow during the quarter, providing substantial capital flexibility for future investments and strategic initiatives.
Management raised its full-year 2026 revenue guidance midpoint to $39.4 billion, signaling confidence in offsetting biosimilar erosion with new launches.
Wells Fargo raised its price target to $435 from $400 on September 4, citing potential upside from HORIZON and pipeline assets like olpasiran.
Repatha recently showed a 20% reduction in death risk for high-risk adults, with heart attack risk reductions emerging as early as six months.
Risk Factors
Mature products faced significant biosimilar pressure, with Prolia revenue declining 32% and XGEVA falling 34% in Q2 2026.
Accelerating biosimilar competition affecting legacy franchises such as Prolia and XGEVA remains a key risk to sustained margin expansion.
Amgen stock experienced a severe decline of 10.1% on September 8, 2026, closing at $393.17 on the Nasdaq. This drop represents the company's steepest single-day fall in approximately 25 years, signaling significant investor concern regarding its current trajectory and market position.
The primary driver of this downturn was a Phase 3 clinical trial setback for Novartis' pelacarsen, an injectable cholesterol-targeting therapy. Investors interpreted this failure as a negative signal for the broader class of similar drugs, raising specific concerns about the efficacy and future prospects of Amgen's own portfolio in the same therapeutic area.
Market sentiment was further weighed down by analyst action from BMO Capital Markets, which cut its rating on Amgen to 'market perform' while maintaining a price target of $450. This downgrade reflects a cautious outlook for the biotechnology giant amidst the challenging environment for cholesterol-lowering treatments.
📉 Amgen stock dropped 10.1% to $393.17, worst decline in ~25 years.
⚠️ Novartis pelacarsen setback raises concerns for Amgen's similar therapies.
📉 BMO downgraded Amgen to 'market perform' with $450 price target.
📉 Amgen stock plummeted 10.1% on September 8, 2026, closing at $393.17 to mark its steepest single-day decline in roughly 25 years.
⚠️ Investors expressed concern that a Phase 3 setback for Novartis' pelacarsen injectable cholesterol drug negatively impacts the outlook for Amgen's similar therapies.
📉 BMO Capital Markets downgraded Amgen to 'market perform' while maintaining a price target of $450, reflecting cautious sentiment on the stock.
BMO cut rating to 'market perform' despite $450 target.
Risk Factors
Amgen shares suffered their steepest single-day decline in about 25 years, dropping 10.1% to close at $393.17.
A Phase 3 setback for Novartis' pelacarsen raised investor concerns regarding the viability of similar cholesterol-targeting therapies within Amgen's own pipeline.
BMO Capital Markets cut its rating on Amgen to 'market perform', indicating a negative shift in analyst sentiment despite maintaining a $450 price target.
Amgen (AMGN) shares fell 10% to $394.38 in Tuesday trading, driven by a sector-wide repricing of Lp(a) cholesterol drugs following Novartis's failed pelacarsen trial. Despite Amgen posting positive Phase 3 results for its IMDELLTRA study in small cell lung cancer on the same morning, investors penalized the company heavily due to its exposure to the broader Lp(a) hypothesis.
The market reaction highlights a specific risk to Amgen's pipeline: its Olpasiran asset, an Lp(a)-lowering therapy currently in Phase 3 OCEAN(a)-Outcomes trials, is now viewed as highly exposed to the class-wide skepticism triggered by Novartis. Analysts suggest that while the mechanism of lowering Lp(a) might be flawed or the trial design at issue, the immediate consequence is a re-rating of all remaining programs in this space.
Amgen's cholesterol franchise remains robust, with Repatha generating $876 million in Q1 2026 revenue and growing 34% year-over-year. However, the stock's decline underscores the market's tendency to treat pipeline assets as correlated bets, even when distinct molecules like Amgen's Olpasiran and Eli Lilly's VERVE-102 utilize different technical approaches.
Looking ahead, investors are advised to monitor follow-up commentary from cardiology leaders and await Amgen's presentation at the 2026 Wells Fargo Healthcare Conference. This upcoming event is expected to be a key catalyst for reframing the narrative around the Lp(a) class and determining whether the recent selloff reflects a failed drug or a fundamental failure of the underlying hypothesis.
📉 Stock dropped 10% amid Lp(a) class concerns after Novartis trial failure.
🧬 IMDELLTRA showed positive Phase 3 results with AstraZeneca's Imfinzi.
⚠️ Olpasiran faces re-rating risk due to Novartis cardiovascular trial miss.
💰 Repatha drove $876M Q1 revenue with 34% year-over-year growth.
📅 Investors await Wells Fargo conference for Lp(a) hypothesis clarity.
📉 Amgen stock dropped 10% to $394.38, interrupting a 23% year-to-date gain, as markets punished the company for its exposure to the Lp(a) drug class following Novartis's trial failure.
🧬 Amgen announced positive Phase 3 results for IMDELLTRA in small cell lung cancer on the same day, showing statistically significant improvement in overall survival with AstraZeneca's Imfinzi.
⚠️ The company's Olpasiran asset is identified as the most exposed pipeline item to the class-wide re-rating caused by Novartis's pelacarsen miss in the cardiovascular outcomes trial.
💰 Repatha continues to drive growth, generating $876 million in Q1 2026 revenue with 34% year-over-year growth and 35% volume expansion.
📅 Investors are watching for Amgen's presentation at the 2026 Wells Fargo Healthcare Conference as the next major catalyst to clarify the Lp(a) hypothesis viability.
🏛️ As a major holding in the Health Care Select Sector SPDR ETF (XLV), Amgen's decline contributed to sector pressure despite Novartis not being a direct component of the fund.
Bullish Signals
IMDELLTRA met Phase 3 endpoint with significant overall survival improvement.
Repatha drove $876M Q1 2026 revenue with 34% YoY growth.
Risk Factors
Shares fell 10% due to sector-wide repricing of Lp(a) pipeline risk.
Investors reweighted odds on cardiovascular programs after Novartis trial failure.
Bullish Signals
Amgen successfully met its primary endpoint in the Phase 3 DeLLphi-305 study for IMDELLTRA, demonstrating statistically significant improvement in overall survival for extensive stage small cell lung cancer.
Repatha remains a high-growth driver within the cholesterol franchise, delivering $876 million in Q1 2026 revenue with 34% year-over-year growth and 35% volume growth.
Risk Factors
Amgen shares fell 10% as the market repriced Lp(a) pipeline risk sectorwide following Novartis's failed pelacarsen trial, directly impacting Amgen's Olpasiran asset.
The failure of Novartis's pelacarsen study has weakened the Lp(a) hypothesis, forcing investors to reweight the odds on Amgen's remaining cardiovascular programs despite its own positive oncology data.
In the first half of 2026, Amgen (NASDAQ:AMGN) has emerged as a strong performer within the large-cap pharmaceutical sector, advancing its stock price by 35% year-to-date to reach $440.84. While trailing Merck's superior 44% gain, Amgen maintains a solid second-place position among peers like Pfizer, which has risen 14%. The article highlights that Amgen's performance is driven by a robust portfolio of over 20 products, with 17 annualizing above $1 billion in sales, positioning it as a resilient player despite the sector's heavy focus on obesity drugs.
Amgen's financial strength is anchored by key franchises including Repatha for cholesterol management, EVENITY for osteoporosis, and TEPEZZA for thyroid eye disease. The company has successfully expanded its oncology capabilities with IMDELLTRA for small cell lung cancer and BLINCYTO, while also addressing severe asthma with TEZSPIRE. Additionally, Amgen leverages a substantial biosimilars business featuring products like AMJEVITA and MVASI, diversifying its revenue streams beyond its core monoclonal antibody offerings.
Looking forward, Amgen is strategically advancing its pipeline with MariTide, an antibody-peptide conjugate currently in Phase 3 development for obesity that features a convenient monthly or less frequent dosing schedule. The company is also exploring candidates such as olpasiran for cardiovascular outcomes and xaluritamig for prostate cancer. As a component of both the Dow Jones Industrial Average and the Nasdaq-100 Index, Amgen offers investors exposure to a diversified mix of established therapies and innovative late-stage developments.
📈 AMGN stock advanced 35% year-to-date in 2026 to $440.84.
💊 Company markets 20+ products, with 17 annualizing above $1B sales.
🔬 Key franchises include Repatha, EVENITY, TEPEZZA, and IMDELLTRA.
🦠 Substantial biosimilars business features AMJEVITA, MVASI, PAVBLU, WEZLANA.
🚀 Pipeline anchored by MariTide Phase 3 obesity candidate with low dosing.
📈 Amgen stock has advanced 35% year-to-date in 2026, reaching a price of $440.84 and securing second place among major drugmakers.
💊 The company markets more than 20 products, with 17 annualizing above $1 billion in sales, providing a stable revenue foundation.
🔬 Key franchises include Repatha for cholesterol, EVENITY for osteoporosis, TEPEZZA for thyroid eye disease, and IMDELLTRA for small cell lung cancer.
🦠 Amgen operates a substantial biosimilars business featuring products such as AMJEVITA, MVASI, PAVBLU, and WEZLANA.
🚀 The pipeline is anchored by MariTide, an antibody-peptide conjugate in Phase 3 development for obesity with monthly or less frequent dosing.
🧬 Additional pipeline candidates include olpasiran for cardiovascular outcomes, xaluritamig for prostate cancer, and dazodalibep for Sjögren's disease.
📊 Amgen is a component of both the Dow Jones Industrial Average and the Nasdaq-100 Index, offering broad market exposure.
🏥 The company addresses severe asthma with TEZSPIRE and continues to innovate across diverse therapeutic areas.
Bullish Signals
Amgen stock has advanced 35% year-to-date in 2026, reaching a price of $440.84 and securing second place among major drugmakers.
The company markets more than 20 products, with 17 annualizing above $1 billion in sales, providing a stable revenue foundation.
Key franchises include Repatha for cholesterol, EVENITY for osteoporosis, TEPEZZA for thyroid eye disease, and IMDELLTRA for small cell lung cancer.
Amgen operates a substantial biosimilars business featuring products such as AMJEVITA, MVASI, PAVBLU, and WEZLANA.
The pipeline is anchored by MariTide, an antibody-peptide conjugate in Phase 3 development for obesity with monthly or less frequent dosing.
Additional pipeline candidates include olpasiran for cardiovascular outcomes, xaluritamig for prostate cancer, and dazodalibep for Sjögren's disease.
Amgen is a component of both the Dow Jones Industrial Average and the Nasdaq-100 Index, offering broad market exposure.
The company addresses severe asthma with TEZSPIRE and continues to innovate across diverse therapeutic areas.
Amgen Inc. (NASDAQ: AMGN) reported significant findings from a prespecified secondary analysis of the Phase 3 VESALIUS-CV trial, indicating that its PCSK9 inhibitor, Repatha, reduced the risk of all-cause mortality by 20% in high-risk adults without prior heart attacks or strokes. The study, which followed over 12,000 patients for a median of 4.6 years, showed that this mortality benefit began to appear after approximately 1.5 years of treatment.
Beyond the mortality data, Repatha demonstrated robust efficacy in reducing major cardiovascular events, lowering the risk of coronary heart disease death, myocardial infarction, or ischemic stroke by 25%. The drug also significantly reduced the risk of a broader cardiovascular composite by 19% and lowered LDL-C levels to 45 mg/dL at 48 weeks compared to 109 mg/dL for placebo. These results reinforce the drug's value in patients with uncontrolled LDL-C despite standard therapy.
The commercial implications of these findings center on expanding Repatha's use earlier in treatment protocols, potentially before a patient's first major cardiovascular event. With the FDA having broadened the U.S. indication in 2025 and the European Commission expanding it in August 2026 based on VESALIUS-CV data, Amgen now faces the challenge of translating stronger mortality evidence into broader guideline adoption, payer reimbursement, and physician prescribing confidence to realize market growth.
Despite the positive clinical data, practical barriers remain, including Repatha's injectable nature versus lower-cost oral alternatives like statins and ezetimibe. The article notes that while the evidence improves the case for earlier use, the ultimate market expansion will depend on absolute benefit realization, reimbursement access, and patient willingness to adopt an injectable regimen over established oral therapies.
📈 VESALIUS-CV trial shows 20% relative risk reduction in all-cause mortality for high-risk adults.
🫀 Repatha lowers risk of heart disease death, MI, or stroke by 25%.
🏥 FDA and EU expanded Repatha indications in 2025 and August 2026 respectively.
💰 Amgen faces adoption barriers due to reimbursement issues and injectable format.
📉 Mortality benefit was a secondary analysis requiring careful interpretation of absolute risk.
📈 Amgen reported a 20% relative risk reduction in all-cause mortality for high-risk adults treated with Repatha in the VESALIUS-CV trial.
💉 The study enrolled over 12,000 patients and followed them for a median of 4.6 years to assess long-term outcomes.
🫀 Repatha reduced the risk of coronary heart disease death, myocardial infarction, or ischemic stroke by 25% in the trial population.
📉 LDL-C levels reached a median of 45 mg/dL at 48 weeks with Repatha compared to 109 mg/dL for placebo.
🏥 The FDA broadened Repatha's U.S. indication in 2025 for adults at increased risk of major cardiovascular events due to uncontrolled LDL-C.
🇪🇺 The European Commission expanded Repatha's indication in August 2026 based on the VESALIUS-CV trial results.
📊 Approximately 9 million patients have received Repatha globally across 51 clinical trials over the last 15 years.
💰 Amgen may not need a new patient population for growth but must overcome adoption barriers related to reimbursement and prescribing behavior.
💉 Repatha is an injectable drug, which presents a practical barrier compared to lower-cost oral treatments like statins and ezetimibe.
📉 The mortality benefit was a prespecified secondary analysis, not the trial's primary endpoint, requiring careful interpretation of absolute vs. relative risk.
👥 66 hedge funds held Amgen Inc. at the end of Q2 2026, up from 65 funds three months earlier.
📈 The evidence supports using Repatha earlier in treatment for high-risk patients with uncontrolled LDL-C despite standard therapy.
Bullish Signals
Repatha cut all-cause mortality risk by 20% in VESALIUS-CV trial.
Study of 12,000+ patients showed benefit after 1.5 years.
Repatha lowered major cardiovascular event risk by 25%.
LDL-C dropped to 45 mg/dL vs 109 mg/dL placebo.
FDA expanded Repatha indication in 2025 for high-risk adults.
Risk Factors
Mortality data is relative risk without absolute event rates.
Study patients limited generalizability to broader cholesterol groups.
Injectable Repatha faces adoption barriers vs. lower-cost oral drugs.
Payer restrictions may slow Repatha market growth access.
Impact on patient persistence remains unproven.
Bullish Signals
Amgen reported that Repatha reduced the risk of all-cause mortality by 20% in a prespecified secondary analysis of the Phase 3 VESALIUS-CV trial.
The study enrolled more than 12,000 high-risk adults and followed them for a median of 4.6 years, showing the mortality benefit began after approximately 1.5 years.
Repatha reduced the risk of coronary heart disease death, myocardial infarction, or ischemic stroke by 25% in the trial population.
The drug lowered the risk of a broader cardiovascular composite by 19% and reduced the risk of myocardial infarction by 36%.
In a lipid substudy, median LDL-C at 48 weeks reached 45 mg/dL with Repatha compared to 109 mg/dL for placebo.
The FDA broadened Repatha's U.S. indication in 2025 to adults at increased risk of major cardiovascular events because of uncontrolled LDL-C.
The European Commission expanded its indication in August 2026 based on the VESALIUS-CV trial results.
Repatha has been studied for 15 years across 51 clinical trials involving more than 57,000 patients, with approximately 9 million patients receiving the drug globally.
Risk Factors
The reported 20% mortality figure is a relative risk reduction, and Amgen did not provide absolute mortality event rates in the announcement.
The enrolled patients were carefully selected to have established atherosclerotic disease or high-risk diabetes, limiting broad generalizability to everyone with elevated cholesterol.
Repatha is an injectable drug, while statins and ezetimibe are lower-cost oral treatments, creating a practical barrier to adoption.
Payer restrictions can slow access to Repatha, potentially hindering the translation of clinical evidence into market growth.
The effect of the new mortality evidence on patient persistence remains unproven.
Amgen (AMGN) has demonstrated strong market confidence following a significant revision of its full-year revenue guidance on August 4, which the stock market immediately rewarded with an instant 4.6% gain and continued climbing momentum. The company's current performance is driven by a robust portfolio of six key growth drivers that collectively grew 26% year-over-year and now represent nearly 70% of total product sales. Additionally, the business showed exceptional breadth in the last quarter, with 22 different products delivering double-digit sales growth, providing the management team with the confidence to navigate competitive pressures effectively.
The stock's recent surge reflects a dual narrative: investors are paying for Amgen's proven ability to execute on its current business model while simultaneously betting on the transformative potential of its late-stage pipeline. The primary focus of this future growth is MariTide, an experimental obesity drug designed for monthly therapy with the potential for as few as four or six doses per year, offering a distinct advantage over weekly injection competitors. However, this strategic pivot introduces significant risk, as the company must successfully navigate massive Phase III trials and prove its profile in a fiercely competitive market to justify the premium valuation currently priced into the stock.
Analysts and traders view Amgen's current trajectory with cautious optimism, noting that options markets are pricing in high volatility at 30%, which sits in the 93rd percentile of its one-year range. This elevated implied volatility suggests the market expects a major move around upcoming catalysts, such as earnings reports or pipeline updates, indicating that the reward for owning the stock comes with the potential for sharp price swings. The core investment thesis hinges on whether Amgen can successfully transition from its current execution-heavy growth phase to winning the high-stakes lottery of its late-stage drug development without eroding margins or failing to meet market expectations.
💊 Six growth drivers grew 26% YoY and now represent ~70% of sales.
🚀 Double-digit sales growth occurred across 22 products in the last quarter.
⚠️ MariTide faces high risk navigating Phase III trials against weekly competitors.
📉 Implied volatility sits at 30%, ranking in the 93rd percentile of range.
📈 Amgen raised its full-year revenue guidance on August 4, prompting an immediate 4.6% stock price increase and sustained upward momentum.
💊 The company's current engine is powered by six key growth drivers that grew 26% year-over-year and now account for nearly 70% of total product sales.
🚀 Amgen reported double-digit sales growth across 22 different products in the last quarter, demonstrating broad business strength.
🔬 The late-stage pipeline features MariTide, an experimental obesity drug designed for monthly therapy with only 4 to 6 doses per year.
⚠️ MariTide faces high risk as it must navigate massive Phase III trials and compete in a crowded market against weekly injection alternatives.
📉 Options markets show Amgen's implied volatility at 30%, placing it in the 93rd percentile of its one-year range due to expected turbulence.
🎯 Investors are currently paying a premium for Amgen, betting on its ability to win the high-stakes lottery of late-stage drug development.
📊 The stock is trading near its 52-week high as management executes today while making massive bets on future vision.
Bullish Signals
Management raised full-year revenue guidance on August 4, signaling strong confidence in the business and triggering an immediate 4.6% stock price increase.
The company's core engine is firing with six key growth drivers growing 26% year-over-year, now representing nearly 70% of total product sales.
Amgen demonstrated exceptional breadth in the last quarter with 22 different products delivering double-digit sales growth simultaneously.
The late-stage pipeline includes MariTide, a potential game-changer in obesity treatment designed for monthly therapy with only 4 to 6 doses per year.
Risk Factors
The stock carries high risk as investors are paying a premium for the company's vision of tomorrow rather than just its proven execution today.
MariTide faces a high-wire act requiring successful navigation of massive Phase III trials in a fiercely competitive market to validate its potential.
Options markets price in significant turbulence with implied volatility at 30%, indicating the stock could experience sharp swings around upcoming catalysts.
Your Privacy
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Measure audience engagement and site statistics to understand how our services are used (Google Analytics)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
You can accept all cookies or configure your preferences. You can change them at any time via the "Manage Cookies" link in the footer.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Analytics cookies
Help us understand how visitors interact with our website using Google Analytics. These cookies collect information anonymously.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
